Roots Pharmaceutical Company Ltd.

What Roots Pharmaceutical Company Ltd. does

Roots Pharmaceutical Company W.L.L is a Kuwait-headquartered, privately held pharmaceutical commercialization company founded in 2006 that acquires, in-licenses, markets, and commercializes innovative prescription pharmaceuticals across the GCC and broader MENA region, with a therapeutic focus on Rare Diseases, Oncology, Immunology, and Neurology alongside a broader portfolio spanning Aesthetic Medicine, Allergy, Analgesics, Anti-Infective, Cardiovascular, Dermatology, ENT, Erectile Dysfunction, GIT, Medical Devices, and Pediatric categories. Its product set of approximately 50+ SKUs includes CE-marked aesthetic-medicine lines (RRS Injectables Class III, Skin Tech chemical peelings and post-peel creams, HAPPY Intim intimate rejuvenation), rare-disease treatments (Fomepizole, Trientine Hydrochloride, Carglumic Acid), oncology (Carmustine), and standard primary-care pharmaceuticals. The underlying operating capability covers the full commercialization stack: medical affairs, pharmacovigilance, regulatory and registration processes, marketing, market access, and strategic governmental affairs, delivered through direct HCP engagement via field sales and Medical Science Liaison teams and through regional pharmaceutical distribution partners.

Roots generates revenue by commercializing in-licensed and proprietary prescription products across multiple MENA markets at quote-based prices negotiated through regulatory and market access channels, using a sales-led GTM reinforced by active participation in industry events such as Arab Health, BIO-Europe Spring, and CPHI Riyadh. Its customers are healthcare professionals, specialists, hospitals, and pharmacies; its principal commercial counterparties are international pharmaceutical licensors and regional partners (SAJA, SUDAIR, MENAGEN, WAYMADE) that anchor its in-licensing pipeline. The company expanded from a Kuwait-only footprint to a MENA-wide operating scope beginning in 2019, and in October 2025 launched its first Roots Health Summit in Al Alamein, convening over 100 physicians to extend its KOL engagement platform. Leadership is concentrated in five senior executives with 20+ years of MENA pharmaceutical experience drawn from Novartis, Algorithm Sal Biologix, and prior regional commercial roles, supporting its positioning as a specialized commercialization partner for international pharmaceutical companies seeking access to the MENA market.

Name

Roots Pharmaceutical Company Ltd.

Legal name

Roots Pharmaceutical Company W.L.L

Website

https://rootspharmaceutical.com

Company type

Private

Founded year

2006

Operating status

Operating

Headcount range

11–50 employees

Short description

Roots Pharmaceutical Company W.L.L is a Kuwait-headquartered, privately held pharmaceutical commercialization company founded in 2006 that acquires, in-licenses, markets, and distributes innovative prescription pharmaceuticals across 13 therapeutic categories to physicians, hospitals, and pharmacies throughout the GCC and MENA region.

Ownership category

akta.pro rank

Product category

Specialty Pharmaceuticals

NAICS

Drugs and Druggists' Sundries Merchant Wholesalers (424210), Drugs and Druggists' Sundries Merchant Wholesalers (42421), Drugs and Druggists' Sundries Merchant Wholesalers (4242)

SIC

Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro primary industry

Dermatology & Aesthetics Pharmaceuticals (HLAIAAAK)

Keywords

• Specialty pharmaceuticals
• Aesthetic medicine products
• Rare disease treatments
• Pharmaceutical commercialization
• MENA region distribution

Headquarters

HQ city

Al Kuwait

HQ country

Kuwait

HQ region

Middle East

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Personnel, Marketing or Sales, Operations, Technology or R&D

Revenue model

1. Pharmaceutical Product Sales: Revenue generated through commercialization and marketing of innovative prescription pharmaceuticals. The company acquires and in-licenses pharmaceutical products and commercializes them across the MENA region, serving unmet medical needs in therapeutic areas including Rare Diseases, Oncology, Immunology, and Neurology.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels4 records

Core offering

Roots Pharmaceutical Company W.L.L acquires, in-licenses, markets, and commercializes a portfolio of innovative prescription pharmaceuticals, aesthetic medicine products, and medical devices across 13 therapeutic categories in Kuwait, the GCC, and the broader MENA region. The company distributes branded specialty products in Rare Diseases, Oncology, Immunology, Neurology, Dermatology, and Aesthetic Medicine through direct engagement with healthcare professionals and a regional distribution network.

Product overview

Roots Pharmaceutical Company W.L.L. is a pharmaceutical company distributing a diverse portfolio of products across 13 therapeutic categories including Aesthetic Medicine, Allergy, Analgesics, Anti-Infective, Cardiovascular, Dermatology, ENT, Erectile Dysfunction, GIT (Gastrointestinal), Medical Devices, Oncology, Pediatric, and Rare Diseases. The company's aesthetic medicine portfolio includes Skin Tech Pharma Group products (RRS injectable medical devices, chemical peelings, post-peel creams), HAPPY Intim intimate rejuvenation products, and various skincare products. The therapeutic pharmaceuticals span multiple drug classes including antihistamines, NSAIDs, antibiotics, statins, PPIs, and specialized treatments for rare diseases and oncology. Medical devices include blood pressure monitors, thermometers, and nebulizers. The company operates in Kuwait and the MENA region, established in 2006 with expansion across GCC and MENA markets since 2019.

Differentiator

Problem solved

Functional benefit

Products and services

• First Roots Health Summit Proprietary multi-specialty healthcare summit bringing together physicians, specialists, and key opinion leaders for evidence-based clinical sessions, health-tech transformation lectures, digital therapy advances, and aesthetic medicine workshops in the MENA region.
• Fomepizole Competitive inhibitor of alcohol dehydrogenase used as antidote primarily for toxic alcohol poisoning including methanol and ethylene glycol ingestion, distributed by Roots Pharmaceutical as a Rare Disease specialty pharmaceutical in the MENA region.
• Trientine Hydrochloride Chelating compound for removal of excess copper from the body, available as 250 mg capsules for oral administration, distributed as a Rare Disease specialty pharmaceutical for Wilson's disease in the MENA region.
• Carglumic Acid Medication that helps eliminate high ammonia levels in blood due to N-acetylglutamate synthase deficiency or isovaleric acidemia, methylmalonic acidemia, or propionic acidemia, distributed as a Rare Disease specialty pharmaceutical in the MENA region.
• Carmustine 100 mg Anticancer nitrosourea medication that slows cancer growth, effective for brain tumors, brain metastasis, non-Hodgkin's lymphoma, Hodgkin disease, and as conditioning treatment prior to autologous hematopoietic stem cell transplantation, distributed by Roots Pharmaceutical as an oncology specialty product in the MENA region.
• Prolacta Bioscience Humavant HMF 100% lacto-engineered human milk-based neonatal nutritional products for exclusive human milk diet (EHMD) that can increase survival rates and reduce complications in premature infants, distributed as a Pediatric specialty nutritional product in the MENA region.
• RRS Injectables Complete line of CE Class III sterile injectable medical devices for face, body, hair, and intimate area treatments, manufactured in conformity with Directive 42/93/EEC, distributed as part of the Skin Tech Pharma Group aesthetic medicine portfolio in the MENA region.
• HAPPY intim Complete CE marked professional treatment approach for aesthetic medicine and gynecology specialists covering genital bleaching, intimate rejuvenation, vaginal tightening, and skin nursing, distributed as a comprehensive intimate aesthetic medicine solution in the MENA region.
• Benebellum Treatment dedicated to hyperpigmentation and blue light skin consequences based on cutting-edge selective molecule technology, distributed as an aesthetic medicine dermatology product in the MENA region.
• Skin Tech Chemical Peelings Medical peeling formulas covering all depths from superficial to very deep to treat fine lines, photo-aging, acne scars, pigment problems, melasma, keratoses, and stretch marks, legally registered and manufactured under GMP and ISO 13485 certifications as part of the Skin Tech Pharma Group aesthetic medicine portfolio.
• My-Pressure 1.0 Fully automatic digital blood pressure monitor for upper arm providing fast, reliable, and accurate readings, clinically certified per European Society of Hypertension protocol, distributed as a medical device in the MENA region.
• T-Flash Infrared digital thermometer for use on patients of any age with one-second temperature detection and no body contact required, distributed as a medical device in the MENA region.
• Artiz (Cetirizine) Second-generation antihistamine that selectively blocks H1 receptors, providing relief from allergic symptoms such as sneezing, itching, runny nose, and hives, distributed as an allergy pharmaceutical in the MENA region.
• Ivarin (Rosuvastatin) HMG-CoA reductase inhibitor (statin) that lowers cholesterol by inhibiting the enzyme responsible for cholesterol synthesis, reducing LDL and increasing HDL cholesterol, distributed as a cardiovascular pharmaceutical in the MENA region.

Quantifiable outcome

• Swiftest time to peak sales in the MENA region for partnered pharmaceutical products

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Four partnerships are on record, tiered core.

• SAJAcoreStrategic or Co-development Partner · 1 January 2024SAJA is a major pharmaceutical player in the KSA market. ROOTS Pharmaceutical connected with SAJA during CPHI Riyadh 2024 to explore business opportunities and outsourcing collaborations in the Kingdom of Saudi Arabia market.
• SUDAIRcoreStrategic or Co-development Partner · 1 January 2024SUDAIR is a key pharmaceutical company in the KSA market. ROOTS Pharmaceutical engaged with SUDAIR during CPHI Riyadh 2024 to explore outsourcing opportunities and collaborations aligned with the region's dynamic healthcare landscape.
• MENAGENcoreStrategic or Co-development Partner · 1 January 2024ROOTS Pharmaceutical engaged with MENAGEN booth at CPHI Riyadh 2024, with discussions progressing toward partnership activation. This collaboration represents a strategic focus on building long-term, value-driven relationships.
• WAYMADE PharmaceuticalcoreChannel Partner/ Reseller/ Distributor · 1 January 2024WAYMADE is an existing partner with whom ROOTS holds ongoing collaboration. Meetings at CPHI Riyadh 2024 focused on expanding the portfolio of collaborations to enhance ability to meet evolving needs of healthcare providers and patients.

Scale indicators3 records

Recent moves6 records

Expansion highlights4 records

Direct peers

• Eva Pharma: Egyptian pharmaceutical company with rapidly growing MENA footprint across Rx and specialty categories. Comparable in regional expansion strategy (MENA-wide), therapeutic breadth, and partner-driven growth.
• Julphar (Gulf Pharmaceutical Industries): Largest UAE-headquartered pharmaceutical manufacturer with broad GCC distribution across generics, specialty, and consumer health. Highly comparable to Roots in geographic focus (GCC/MENA), multi-therapeutic portfolio breadth, and distribution-led model.
• Tabuk Pharmaceuticals: Saudi-headquartered pharmaceutical company marketing branded generics and specialty products across MENA. Comparable distribution-and-commercialization model and overlapping therapeutic focus (cardio, CNS, oncology).
• Pharma International (Jordan): Jordan-based pharmaceutical manufacturer with extensive MENA distribution across CNS, cardiovascular, dermatology, and anti-infective categories. Comparable product categories and regional go-to-market.
• EIPICO (Egyptian International Pharmaceutical Industries Company): One of Egypt's largest pharmaceutical manufacturers distributing across MENA in cardiovascular, anti-infective, GIT, and dermatology. Comparable therapeutic breadth and MENA-wide regional reach.
• SPIMACO (Saudi Pharmaceutical Industries & Medical Appliances Corporation): Leading KSA-listed pharmaceutical manufacturer and distributor with multi-category Rx portfolio across cardiovascular, anti-infective, GIT, and dermatology. Direct peer given overlapping therapeutic categories and shared GCC commercial footprint.

Broad incumbents

• Hikma Pharmaceuticals: Jordanian-founded multinational with deep MENA presence across branded generics, injectables, and specialty. Significantly larger incumbent operating the same regional commercialization playbook as Roots, with broader portfolio.
• Cipla: Indian-headquartered multinational with a large MENA commercial presence across respiratory, anti-infective, cardiovascular, and dermatology. Comparable breadth and partner-licensing model in emerging markets.
• AstraZeneca MENA: Multinational with direct presence across MENA including oncology, rare disease, immunology, and respiratory — the same specialty areas Roots targets. Relevant as the kind of originator that may in-house MENA distribution rather than partner with Roots.

Emerging players

• Algorith Sal Biologix: Former employer of Roots' Regulatory Director Ahmed El Roubi; MENA-focused biologics and specialty distributor across neurology, hematology/oncology, rare disease. Comparable therapeutic mix and MENA focus.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/roots-pharmaceutical-company

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Roots Pharmaceutical Company Ltd.